| David W Manning, MD | |
|
180 Harvester Dr Ste 110, Burr Ridge, IL 60527-6686 | |
| (773) 834-4064 | |
| Not Available |
| Full Name | David W Manning |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 27 Years |
| Location | 180 Harvester Dr Ste 110, Burr Ridge, Illinois |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1962567792 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207X00000X | Orthopaedic Surgery | (Illinois) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Aspire Home Healthcare, Llc | Morton grove, IL | Home health agency |
| One Home Health Agency, Ltd | Crystal lake, IL | Home health agency |
| Palos Community Hospital Home Health Care | Lemont, IL | Home health agency |
| Ati Home Health | Oak brook, IL | Home health agency |
| Apple Home Healthcare | Chicago, IL | Home health agency |
| Northwestern Memorial Hospital | Chicago, IL | Hospital |
| Central Dupage Hospital | Winfield, IL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Northwestern Medical Faculty Foundation | 4587576814 | 3255 |
| Rci (wrs), Llc. | 5092624510 | 312 |
News Archive
A study led by researchers at Boston University School of Medicine (BUSM) provides novel insight into the impact that Huntington's disease has on the brain.
The GAVI Alliance "is to help protect more than 180,000 girls in eight countries across Africa and Asia from cervical cancer by funding immunization projects with vaccines from Merck and GlaxoSmithKline," Reuters reports in an article examining the group's efforts to vaccinate young women with Merck's Gardasil and GSK's Cervarix, "the world's only two approved shots designed to protect against the sexually transmitted human papillomavirus (HPV) that causes the vast majority of cervical cancer cases."
Electrochemical Oxygen Concepts, the developer of a unique and innovative chronic wound treatment device, announced it has been added to Marathon Medical's existing Federal Supply Schedule (FSS) contract, administered by The Department of Veterans Affairs.
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today updated positive results from its Phase 1/2 clinical study of lumasiran, an investigational, subcutaneously administered RNAi therapeutic targeting glycolate oxidase for the treatment of primary hyperoxaluria type 1.
An analysis of the NRG Oncology clinical trial NRG-RTOG 9202 showed that the interval of time to biochemical failure, or the time it takes for previously treated cancer to return as indicated by prostate specific antigen rise, could be used as a surrogate endpoint for locally advanced prostate cancer.
› Verified 2 days ago
| Entity Name | Northwestern Medical Faculty Foundation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346235314 PECOS PAC ID: 4587576814 Enrollment ID: O20031105000541 |
News Archive
A study led by researchers at Boston University School of Medicine (BUSM) provides novel insight into the impact that Huntington's disease has on the brain.
The GAVI Alliance "is to help protect more than 180,000 girls in eight countries across Africa and Asia from cervical cancer by funding immunization projects with vaccines from Merck and GlaxoSmithKline," Reuters reports in an article examining the group's efforts to vaccinate young women with Merck's Gardasil and GSK's Cervarix, "the world's only two approved shots designed to protect against the sexually transmitted human papillomavirus (HPV) that causes the vast majority of cervical cancer cases."
Electrochemical Oxygen Concepts, the developer of a unique and innovative chronic wound treatment device, announced it has been added to Marathon Medical's existing Federal Supply Schedule (FSS) contract, administered by The Department of Veterans Affairs.
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today updated positive results from its Phase 1/2 clinical study of lumasiran, an investigational, subcutaneously administered RNAi therapeutic targeting glycolate oxidase for the treatment of primary hyperoxaluria type 1.
An analysis of the NRG Oncology clinical trial NRG-RTOG 9202 showed that the interval of time to biochemical failure, or the time it takes for previously treated cancer to return as indicated by prostate specific antigen rise, could be used as a surrogate endpoint for locally advanced prostate cancer.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| David W Manning, MD 5841 S Maryland Ave # Mc1099, Chicago, IL 60637-1447 Ph: () - | David W Manning, MD 180 Harvester Dr Ste 110, Burr Ridge, IL 60527-6686 Ph: (773) 834-4064 |
News Archive
A study led by researchers at Boston University School of Medicine (BUSM) provides novel insight into the impact that Huntington's disease has on the brain.
The GAVI Alliance "is to help protect more than 180,000 girls in eight countries across Africa and Asia from cervical cancer by funding immunization projects with vaccines from Merck and GlaxoSmithKline," Reuters reports in an article examining the group's efforts to vaccinate young women with Merck's Gardasil and GSK's Cervarix, "the world's only two approved shots designed to protect against the sexually transmitted human papillomavirus (HPV) that causes the vast majority of cervical cancer cases."
Electrochemical Oxygen Concepts, the developer of a unique and innovative chronic wound treatment device, announced it has been added to Marathon Medical's existing Federal Supply Schedule (FSS) contract, administered by The Department of Veterans Affairs.
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today updated positive results from its Phase 1/2 clinical study of lumasiran, an investigational, subcutaneously administered RNAi therapeutic targeting glycolate oxidase for the treatment of primary hyperoxaluria type 1.
An analysis of the NRG Oncology clinical trial NRG-RTOG 9202 showed that the interval of time to biochemical failure, or the time it takes for previously treated cancer to return as indicated by prostate specific antigen rise, could be used as a surrogate endpoint for locally advanced prostate cancer.
› Verified 2 days ago
Terrance D Peabody, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 180 Harvester Dr Ste 110, Burr Ridge, IL 60527 Phone: 773-834-4064 | |
Roderick R Birnie, MD Orthopedic Surgery Medicare: Medicare Enrolled Practice Location: 180 Harvester Dr Ste 110, Burr Ridge, IL 60527 Phone: 773-834-4064 |